Obesity/Overweight – Landscape & Forecast – Disease Landscape & Forecast
Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is that available treatments have poor risk-benefit profiles and are expensive. In addition, few novel agents are in development for obesity. Consequently, there is huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such an agent is developed and approved, payers will likely need to restrict its access to limit the impact on finite healthcare budgets.
Questions answered:
- Which metabolic and central pathways have high potential as drug targets?
- What is the prevalence of obesity in the major pharmaceutical markets under study?
- How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy and Saxenda as treatments for obese / overweight patients?
- What is the current level of unmet need according to obesity experts? How will this need be addressed during the 2021-2031 forecast period?
- What is the commercial potential of emerging therapies? How do leaders in the field of obesity treatment rate these drug candidates?
- How will the obesity therapy market evolve over the next 10 years?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 20 country-specific interviews with thought-leading endocrinologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of obesity and drug-treatable overweight by country, including diagnosed and drug-treated populations.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key obesity therapies through 2031, segmented by brands / generics and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Obesity/Overweight - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Obesity / overweight key findings - December 2022
- Key updates
- March 2023
- Q4 2022
- December 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Market outlook
- Key findings
- Market share of drug classes for obesity / overweight: 2021
- Market share of drug classes for obesity / overweight: 2031
- Obesity / overweight SWOT analysis
- Market drivers and constraints
- What factors are driving the market for obesity / overweight?
- What factors are constraining the market for obesity / overweight?
- Patient share by drug class for obesity in the major markets: 2021-2031
- Total obesity sales by drug class in the major markets: 2021-2031
- Sales by obese and drug-eligible overweight subpopulations in the major markets: 2021-2031
- Drug-class-specific trends
- Patient share of Saxenda and Wegovy in the United States: 2021-2031
- Total sales of Saxenda and Wegovy for obesity in the United States: 2021-2031
- Patient share of Saxenda and Wegovy in the major European markets: 2021-2031
- Total sales of Saxenda and Wegovy for obesity in the major European markets: 2021-2031
- Patient share of Wegovy for obesity in Japan: 2021-2031
- Total sales of Wegovy for obesity in Japan: 2021-2031
- Patient share of tirzepatide in the United States: 2021-2031
- Total sales of tirzepatide in the United States: 2021-2031
- Patient share of tirzepatide in the major European markets: 2021-2031
- Total sales of tirzepatide in the major European markets: 2021-2031
- Patient share of tirzepatide in Japan: 2021-2031
- Total sales of tirzepatide in Japan: 2021-2031
- Amylin analogue / GLP-1 receptor agonist FDCs
- Patient share of CagriSema in the United States: 2021-2031
- Total sales of CagriSema in the United States: 2021-2031
- Patient share of Qsymia and Contrave / Mysimba in the United States: 2021-2031
- Total sales of Qsymia and Contrave / Mysimba in the United States: 2021-2031
- Patient share of Contrave / Mysimba in the major European markets: 2021-2031
- Total sales of Contrave / Mysimba in the major European markets: 2021-2031
- Patient share of off-label prescription drugs for obesity in the United States: 2021-2031
- Sales of off-label prescription drugs for obesity in the United States: 2021-2031
- Patient share of off-label prescription drugs for obesity in Europe: 2021-2031
- Sales of off-label prescription drugs for obesity in Europe: 2021-2031
- Patient share of off-label prescription drugs for obesity in Japan: 2021-2031
- Sales of off-label prescription drugs for obesity in Japan: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions - obesity (2021-2031) - December 2022
- Market forecast dashboard - obesity (2021-2031) - December 2022
- Etiology and pathophysiology
- Disease overview
- Etiology
- Pathophysiology
- Natural history
- Major complications related to obesity
- Key pathways and drug targets
- Drug targets in obesity: energy storage
- Drug targets in obesity: energy expenditure
- Drug targets in obesity: gastrointestinal system
- Neural and hormonal mediators of hunger and satiety
- Drug targets in obesity: central nervous system
- Hypothalamic structures of the brain involved in food intake regulation
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Total prevalent cases of obesity: 2021-2031 (millions)
- Total prevalent cases of overweight: 2021-2031 (millions)
- Disease definition, methods, and sources used
- Total prevalent cases of obesity by disease severity: 2021-2031 (millions)
- Disease definition, methods, and sources used
- Total prevalent cases of drug-eligible overweight: 2021-2031 (millions)
- Diagnosed prevalent cases
- Diagnosed prevalent cases of obesity in the mature markets (thousands): 2021-2031
- Diagnosed prevalent cases of drug-eligible overweight in the mature markets (thousands): 2021-2031
- Drug-treated cases of obesity and overweight
- Drug-treated cases of obesity in the mature markets (thousands): 2021-2031
- Drug-treated cases of drug-eligible overweight in the mature markets (thousands): 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for obesity
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for obesity
- Current treatments used for obesity
- Market events impacting the use of key current therapies for obesity
- Wegovy
- Advantages and disadvantages of Wegovy
- Expert insight: Wegovy
- Key results from select clinical trials investigating Wegovy for the treatment of obesity
- Advantages and disadvantages of Saxenda
- Expert insight: Saxenda
- Advantages and disadvantages of Qsymia
- Expert insight: Qsymia
- Advantages and disadvantages of Contrave / Mysimba
- Expert insight: Contrave / Mysimba
- Advantages and disadvantages of Xenical
- Expert insight: Xenical
- Advantages and disadvantages of phentermine
- Expert insight: phentermine
- Advantages and disadvantages of Mazindol
- Expert insight: Mazindol
- Advantages and disadvantages of off-label prescription drugs
- Expert insight: off-label prescription drugs
- Medical practice
- Overview
- Factors influencing drug selection in obesity
- Treatment decision tree for obesity: United States
- Treatment decision tree for obesity: Europe
- Treatment decision tree for obesity: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in obesity / overweight
- Top unmet needs in obesity: current and future attainment
- Expert insight: unmet need in obesity / overweight
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for obesity
- Estimated launch dates of key emerging therapies for the treatment of obesity
- Tirzepatide profile
- Analysis of the clinical development program for tirzepatide
- Expert insight: tirzepatide
- Expectations for launch and sales opportunity of tirzepatide in obesity
- CagriSema profile
- Analysis of the clinical development program for CagriSema
- Expert insight: CagriSema
- Early-phase pipeline analysis
- Select compounds in early-phase development for obesity / overweight
- Key discontinuations and failures in obesity / overweight
- Key discontinuations and failures
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in obesity: United States
- General reimbursement environment: United States
- Key market access considerations in obesity: EU5
- General reimbursement environment: EU5
- Key market access considerations in obesity: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviation
- Obesity bibliography
- Key findings
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.